Is the epidemic getting better? The pharmaceutical industry is facing the last of these shocks

According to statistics, on February 19, the number of new cases in Hubei Province dropped to three figures, and 1209 new discharged cases were found in the province In addition to novel coronavirus pneumonia cases in Hubei, 45 cases were found to be on the decline for sixteenth consecutive days 0 cases of new crown pneumonia confirmed in Liaoning, Fujian, Shanxi and Shanghai were reported Recently, Professor Guan Yi's research group of Hong Kong University and Hu Yanling's research group of Guangxi Medical University announced that pangolin is likely to be the intermediate host of the new tubovirus This provides new evidence that pangolin is a potential intermediate host of new coronavirus Good news has proved that the effect of epidemic prevention and control has been shown all over the country However, the epidemic has brought a great impact on catering, film, tourism, entertainment, clothing retail, transportation, education and training, financial services, real estate, manufacturing and other industries China's WHO announced that novel coronavirus pneumonia constitutes a public health emergency with international concern 62 countries have imposed immigration control on China Many netizens worry that the economy will be affected Earlier, novel coronavirus pneumonia was issued by FDA The FDA said the outbreak may affect the supply chain of medical products, including potential supply interruption or shortage of key medical products in the United States The FDA proactively contacted manufacturers to identify potential supply interruption or shortage In response, the FDA has worked with hundreds of drug and medical device manufacturers and the European Medicines Agency, EMA) and other global regulatory agencies keep in touch to assess and monitor the potential signs and early warning signals of production suspension or interruption due to the outbreak of the epidemic; in addition, the raw materials used in the production of biological products in the United States are from other regions in China and Southeast Asia, and FDA will also keep in touch with the manufacturers of biological products to assess any supply problems of raw materials; sound Ming also said the FDA does not currently conduct inspections in China because of travel warnings issued by the State Department In February, the FDA identified all periodic inspections in China that were either delayed or would use other information to inform decisions to allow products to enter the U.S market China is the world's largest supplier of APIs (active pharmaceutical ingredients), including penicillin, statins and even vitamins, and the outbreak has raised concerns about global supply chain disruption again According to some reports, China accounts for 40% of global API production The World Health Organization and the food and drug administration point out that China's position in this field is increasing day by day In October 2019, the FDA announced that only 28% (510) of the manufacturing facilities of APIs for all controlled drugs supplied to the U.S market are actually located in the United States The vast majority of these manufacturers are overseas, including India; 13% (230) of them are in China On the face of it, this may seem like a balanced diversification, but the number of registered manufacturers of APIs in China more than doubled between 2010 and 2019 Novel coronavirus pneumonia, Rita Numerof, recently released her comments on the strategic business of the pharmaceutical industry caused by the new crown pneumonia Rita numerof said in his article that it may be time for the United States to consider establishing strategic reserves for some key drugs and APIs As far as traditional manufacturing technologies are used for API production, American enterprises cannot offset the labor and other cost advantages represented by China However, the FDA said advanced manufacturing technology could pave the way for the U.S pharmaceutical industry to regain its competitiveness against China and other markets Rita numerof said it could be a good time to rethink its approach and its role in protecting the public at a time when the pharmaceutical industry is under huge scrutiny and strong negative news If the U.S readjusts its strategy, it will also have a great impact on the Chinese pharmaceutical industry, especially the API suppliers Reference source: 1 Coronavirus – strategic questions underlying the break 2 FDA's actions in response to 2019 novel coronavirus at home and abroad Statement: This article only represents the author, not the position of drug intelligence network Please communicate and supplement in the message area If you need to reprint, please be sure to indicate the author and source of the article.